Skip to content
Other

Changes in the fair value of equity securities

Biogen Changes in the fair value of equity securities increased by 3900.0% to $19M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 146.5%, from -$40.9M to $19M.

Analysis

StatementIncome Statement
SectionOther
First reportedQ3 2018
Last reportedQ1 2026Apr 29, 2026
Metric ID: other_increase_decrease_in_equity_securities_fv_ni

Historical Data

11 periods
 Q3 '21Q1 '22Q2 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q1 '25Q3 '25Q1 '26
Value-$426.9M-$191.1M-$78.2M-$79.6M$106.4M-$302.5M-$31.3M-$30.3M-$40.9M-$500K$19M
QoQ Change+55.2%+59.1%-1.8%+233.7%-384.3%+89.7%+3.2%-35.0%+98.8%>999%
YoY Change+58.3%+236.1%+60.7%-128.5%-30.7%+146.5%
Range-$426.9M$106.4M
CAGR-71.2%
Avg YoY Growth+57.1%
Median YoY Growth+59.5%
Current Streak2 quarters growth

Frequently Asked Questions

What is Biogen's changes in the fair value of equity securities?
Biogen (BIIB) reported changes in the fair value of equity securities of $19M in Q1 2026.
How has Biogen's changes in the fair value of equity securities changed year-over-year?
Biogen's changes in the fair value of equity securities increased by 146.5% year-over-year, from -$40.9M to $19M.